Turkey Jostles For Slice Of Biologics Manufacturing Pie
Executive Summary
Many local pharma companies in Turkey have been launching capital investments in new production facilities for biologics and biosimilars in the hope of attracting new foreign partners and have already met with some success, but a number of obstacles remain.
You may also be interested in...
Baxter Divests Serum Business In Turkey Business Rejig
In alignment with the global separation of its Baxalta biopharmaceutical business, Baxter will complete a major reorganization in Turkey by the end of the year that includes the sale of its local serum products portfolio and production equipment to a fast-growing local firm.
Pricing Concerns Delaying Sanofi’s Turkey Insulin Investment?
Despite the political turmoil, Sanofi appears keen to invest in the local manufacturing of an insulin product in Turkey if the government “opens the way”, but is holding off over pricing worries.
Medtech Procurement A Victim Of Turkey’s Ongoing Economic Troubles
The devaluation of the Turkish Lira since May is making imports of medical devices more expensive and putting hospital procurement under renewed pressure. The local medtech industry associations TUMDEF and ARTED describe the problems ̶ and the solutions ̶ to Medtech Insight.